Citations (110)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (18)
Billy J. Molloy, Adam King, Lauren G. Mullin, Lee A. Gethings, Robert Riley, Robert S. Plumb & Ian D. Wilson. (2021) Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC/MS/MS, UPLC/QToF/MS, and ion mobility (IM)-enabled UPLC/QToF/MS. Xenobiotica 51:4, pages 434-446.
Read now
Read now
Xun Gao, Yue Zhang, Tiantian Feng, Lei Cao, Wenjing Wu & Kunming Qin. (2021) Comprehensive identification, fragmentation pattern, and metabolic pathways of gefitinib metabolites via UHPLC-Q-TOF-MS/MS: in vivo study of rat plasma, urine, bile, and faeces. Xenobiotica 51:3, pages 355-365.
Read now
Read now
Zi-Yi Xu & Jun-Ling Li. (2019) Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. OncoTargets and Therapy 12, pages 5467-5484.
Read now
Read now
Toshito Nakagawa, Stephen Fowler, Kenji Takanashi, Kuresh Youdim, Tsuyoshi Yamauchi, Kosuke Kawashima, Mika Sato-Nakai, Li Yu & Masaki Ishigai. (2018) In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes. Xenobiotica 48:6, pages 546-554.
Read now
Read now
Sabrina Rossi, Vincenzo Di Noia, Laura Tonetti, Antonia Strippoli, Michele Basso, Giovanni Schinzari, Alessandra Cassano, Antonio Leone, Carlo Barone & Ettore D'Argento. (2018) Does Sarcopenia Affect Outcome in Patients with Non-Small-Cell Lung Cancer Harboring EGFR Mutations?. Future Oncology 14:10, pages 919-926.
Read now
Read now
Toshihiro Sato, Hajime Ito, Ayaka Hirata, Takaaki Abe, Nariyasu Mano & Hiroaki Yamaguchi. (2018) Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3. Xenobiotica 48:1, pages 73-78.
Read now
Read now
Filippo Alongi, Stefano Arcangeli, Sara Ramella, Niccolò Giaj-Levra, Paolo Borghetti, Rolando D’angelillo, Francesco Ricchetti, Marta Maddalo, Rosario Mazzola, Marco Trovò, Elvio Russi & Stefano Maria Magrini. (2017) From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?. Expert Review of Anticancer Therapy 17:2, pages 157-165.
Read now
Read now
Meng-Jiao Li, Qing He, Mei Li, Feng Luo & Yong-Song Guan. (2016) Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. OncoTargets and Therapy 9, pages 1291-1302.
Read now
Read now
Jing Liu, Ligang Xing, Xue Meng, Jinbo Yue, Xiangjiao Meng, Peng Xie, Xiaolin Li, Li Kong & Jinming Yu. (2016) Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation. OncoTargets and Therapy 9, pages 671-679.
Read now
Read now
C. M. Nijenhuis, J. H. M. Schellens & J. H. Beijnen. (2016) Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review. Drug Metabolism Reviews 48:2, pages 266-280.
Read now
Read now
Ying Yuan, Xiao-Fen Li, Jia-Qi Chen, Cai-Xia Dong, Shan-Shan Weng & Jian-Jin Huang. (2014) Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer. OncoTargets and Therapy 7, pages 841-852.
Read now
Read now
Jayaprakasam Bolleddula, Kevin DeMent, James P. Driscoll, Philip Worboys, Patrick J. Brassil & David L. Bourdet. (2014) Biotransformation and bioactivation reactions of alicyclic amines in drug molecules. Drug Metabolism Reviews 46:3, pages 379-419.
Read now
Read now
Petra Martin, Scott P Owen & Natasha B Leighl. (2013) Gefitinib: Re-Emerging from the Shadows. Lung Cancer Management 2:5, pages 423-437.
Read now
Read now
Derek R Duckett & Michael D Cameron. (2010) Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opinion on Drug Metabolism & Toxicology 6:10, pages 1175-1193.
Read now
Read now
Lynn Campbell, Fiona Blackhall & Nicholas Thatcher. (2010) Gefitinib for the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy 11:8, pages 1343-1357.
Read now
Read now
Martin Reck. (2009) Gefitinib in the treatment of advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy 9:4, pages 401-412.
Read now
Read now
Keith Pratz & Mark Levis. (2008) Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Leukemia & Lymphoma 49:5, pages 852-863.
Read now
Read now
D. McKillop, S. P. Guy, M. P. Spence, J. Kendrew, J. V. Kemp, N. Bushby, P. G. Wood, S. Barnett & M. Hutchison. (2006) Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. Xenobiotica 36:1, pages 29-39.
Read now
Read now
Articles from other publishers (92)
Guizhen Zhu, Yaoyao Zhao, Wenmei Zhang, Yuanyuan Wu, Yuanxing Liu, Guangsheng Guo, Xiayan Wang & Zhihong Liu. (2024) Single-cell mass spectrometry studies of drug metabolism heterogeneity and primary resistance to gefitinib in non-small cell lung cancer cells. Chinese Chemical Letters 35:2, pages 108466.
Crossref
Crossref
Myriam El Biali, Sylvain Auvity, Salvatore Cisternino, Maria Smirnova, Marcus Hacker, Markus Zeitlinger, Severin Mairinger, Nicolas Tournier, Martin Bauer & Oliver Langer. (2023) Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice. Molecular Pharmaceutics 20:11, pages 5877-5887.
Crossref
Crossref
Mohd Abul Kalam, Adel Ali Alhowyan, Sulaiman S. Alhudaithi, Mohd Shahnawaz Khan, Abdullah K. Alshememry & Musaed Alkholief. (2023) Solid Dispersions of Gefitinib with D-α-Tocopherol Polyethylene Glycol-1000 Succinate and 2-Hydroxypropyl β-Cyclodextrin Complex Improved Their Solubility, Dissolution and Apoptosis against A549 Cells. Applied Sciences 13:19, pages 10859.
Crossref
Crossref
Smruti Ranjan Patra, Alka Bali, Madhurima Saha, Joga Singh & Sudhanshu Shekhar. (2023) Method validation and characterization of stress degradation products of gefitinib through UPLC-UV/PDA and LC–MS/TOF studies. International Journal of Mass Spectrometry 490, pages 117070.
Crossref
Crossref
Jiahua Lyu, Ningjing Yang, Ling Xiao, Xinyu Nie, Jing Xiong, Yudi Liu, Min Zhang, Hangyue Zhang, Cunhan Tang, Shiyi Pan, Long Liang, Hansong Bai, Churong Li, Hao Kuang & Tao Li. (2023) Prognostic value of sarcopenia in patients with lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors. Frontiers in Nutrition 10.
Crossref
Crossref
Simon G. Wong & Shuguang Ma. 2023. Overcoming Obstacles in Drug Discovery and Development. Overcoming Obstacles in Drug Discovery and Development
137
174
.
Chung-Ping Yu, Pei-Ling Tsai, Pei-Ying Li, Pei-Wen Hsu, Shiuan-Pey Lin, Pei-Dawn Lee Chao & Yu-Chi Hou. (2022) Cranberry Ingestion Modulated Drug Transporters and Metabolizing Enzymes: Gefitinib Used as a Probe Substrate in Rats. Molecules 27:18, pages 5772.
Crossref
Crossref
Qi Zhao, Zhanxuan E. Wu, Bin Li & Fei Li. (2022) Recent advances in metabolism and toxicity of tyrosine kinase inhibitors. Pharmacology & Therapeutics 237, pages 108256.
Crossref
Crossref
Shaoxing Guan, Xi Chen, Youhao Chen, Guohui Wan, Qibiao Su, Heng Liang, Yunpeng Yang, Wenfeng Fang, Yan Huang, Hongyun Zhao, Wei Zhuang, Shu Liu, Fei Wang, Wei Feng, Xiaoxu Zhang, Min Huang, Xueding Wang & Li Zhang. (2022) FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy. Acta Pharmaceutica Sinica B 12:9, pages 3639-3649.
Crossref
Crossref
Wei Feng, Xi Chen, Shao-xing Guan, Hong-lian Ruan, Yan Huang, Hui-zhen Zhang, Yun-peng Yang, Wen-feng Fang, Hong-yun Zhao, Wei Zhuang, Shuang Xin, You-hao Chen, Fei Wang, Yue Gao, Min Huang, Xue-ding Wang & Li Zhang. (2021) Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics. Acta Pharmacologica Sinica 43:7, pages 1857-1864.
Crossref
Crossref
Antonia Högnäsbacka, Alex Poot, Danielle Vugts, Guus van Dongen & Albert Windhorst. (2022) The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor. Pharmaceuticals 15:4, pages 450.
Crossref
Crossref
Robert S. Plumb, Giorgis Isaac, Paul D. Rainville, Jason Hill, Lee A. GethingsKelly A. Johnson, Joshua Lauterbach & Ian D. Wilson. (2021) High Throughput UHPLC-MS-Based Lipidomics Using Vacuum Jacketed Columns. Journal of Proteome Research 21:3, pages 691-701.
Crossref
Crossref
Thu-Lan T. Luong, Chelsea N. Powers, Brian J. Reinhardt & Peter J. Weina. (2022) Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine. Current Research in Pharmacology and Drug Discovery 3, pages 100112.
Crossref
Crossref
S. R. Patra, A. Bali & M. Saha. (2021) Derivative Spectrophotometric Methods for Determination of Gefitinib in Bulk and in Formulation. Journal of Applied Spectroscopy 88:5, pages 1088-1094.
Crossref
Crossref
Nikunj Tanna, Lauren G. Mullin, Paul D. Rainville, Ian D. Wilson & Robert S. Plumb. (2021) Improving LC/MS/MS-based bioanalytical method performance and sensitivity via a hybrid surface barrier to mitigate analyte – Metal surface interactions. Journal of Chromatography B 1179, pages 122825.
Crossref
Crossref
Billy Molloy, Lauren Mullin, Adam King, Lee A. Gethings, Robert S. Plumb & Ian D. Wilson. (2021) The Pharmacometabodynamics of Gefitinib after Intravenous Administration to Mice: A Preliminary UPLC–IM–MS Study. Metabolites 11:6, pages 379.
Crossref
Crossref
Jiangxia Du, Guanqun Li, Liyu Jiang, Xiaochen Zhang, Zhifei Xu, Hao Yan, Ziye Zhou, Qiaojun He, Xiaochun Yang & Peihua Luo. (2021) Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib. Toxicology Letters 338, pages 1-9.
Crossref
Crossref
Shaoxing Guan, Xi Chen, Shuang Xin, Shu Liu, Yunpeng Yang, Wenfeng Fang, Yan Huang, Hongyun Zhao, Xia Zhu, Wei Zhuang, Fei Wang, Wei Feng, Xiaoxu Zhang, Min Huang, Xueding Wang & Li Zhang. (2021) Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer. Translational Oncology 14:1, pages 100951.
Crossref
Crossref
Thu-Lan T. Luong, Michael J. McAnulty, David L. Evers, Brian J. Reinhardt & Peter J. Weina. (2021) Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan. Current Research in Toxicology 2, pages 217-224.
Crossref
Crossref
Chao Wang, Jingui Zhang, Simin Zhou, Limei Yu, Fangxuan Han, Ren Ling & Jin Ling. (2020) Tentative identification of gefitinib metabolites in non-small-cell lung cancer patient plasma using ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry. PLOS ONE 15:7, pages e0236523.
Crossref
Crossref
Can Zhao, Huifeng Hao, Haiyu Zhao, Wei Ren, Yanna Jiao, Guo An, Hong Sun, Shuyan Han & Pingping Li. (2020) Marsdenia tenacissima extract promotes gefitinib accumulation in tumor tissues of lung cancer xenograft mice via inhibiting ABCG2 activity. Journal of Ethnopharmacology 255, pages 112770.
Crossref
Crossref
Angeliki P. Kourounakis, Dimitrios Xanthopoulos & Ariadni Tzara. (2019) Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules. Medicinal Research Reviews 40:2, pages 709-752.
Crossref
Crossref
Shingo Oda, Nanaka Miyazaki, Koichi Tsuneyama & Tsuyoshi Yokoi. (2020) Exacerbation of gefitinib-induced liver injury by glutathione reduction in mice. The Journal of Toxicological Sciences 45:8, pages 493-502.
Crossref
Crossref
Marie‐Noëlle Paludetto, Florent Puisset, Etienne Chatelut & Cécile Arellano. (2019) Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity. Medicinal Research Reviews 39:6, pages 2105-2152.
Crossref
Crossref
Can Zhao, Nan Zheng, Fen Yang, Shu‐Yan Han & Ping‐Ping Li. (2019) A validated high‐performance liquid chromatography–tandem mass spectrometry method for quantification of gefitinib and its main metabolites in xenograft mouse tumor: Application to a pharmacokinetics study. Biomedical Chromatography 33:11.
Crossref
Crossref
Isabelle Solassol, Frédéric Pinguet & Xavier Quantin. (2019) FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management. Biomolecules 9:11, pages 668.
Crossref
Crossref
Pramod C. Nair, Ross A. McKinnon & John O. Miners. (2019) Computational Prediction of the Site(s) of Metabolism and Binding Modes of Protein Kinase Inhibitors Metabolized by CYP3A4. Drug Metabolism and Disposition 47:6, pages 616-631.
Crossref
Crossref
Toshio Kawata, Mitsuo Higashimori, Yohji Itoh, Helen Tomkinson, Martin G. Johnson, Weifeng Tang, Fredrik Nyberg, Haiyi Jiang & Yusuke Tanigawara. (2019) Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 83:5, pages 849-858.
Crossref
Crossref
Min YuQian ZhaoYanying LiShuang ZhangYong XuYouling GongJiang ZhuZhenyu DingJin WangFeng PengYongsheng WangMeijuan HuangLi RenYou LuYongmei Liu. (2018) Progression of Central Nervous System Metastases in Advanced Nonsmall Cell Lung Cancer Patients Effectively Treated with First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor. Cancer Biotherapy and Radiopharmaceuticals 33:10, pages 421-426.
Crossref
Crossref
Kwon-Yeon Weon, Min Gi Kim, Soyoung Shin, Tae Hwan Kim, Sang Hoon Joo, Eunsook Ma, Seok Won Jeong, Sun Dong Yoo, Yu Seok Youn & Beom Soo Shin. (2018) Alterations of Gefitinib Pharmacokinetics by Co-administration of Herbal Medications in Rats. Chinese Journal of Integrative Medicine 24:6, pages 460-466.
Crossref
Crossref
Michael Gerisch, Thomas Schwarz, Dieter Lang, Gabriele Rohde, Stefanie Reif, Isabelle Genvresse, Susanne Reschke, Dorina van der Mey & Camille Granvil. (2017) Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers. Cancer Chemotherapy and Pharmacology 80:3, pages 535-544.
Crossref
Crossref
Yaakov Cass, Thomas H Connor & Alexander Tabachnik. (2016) Safe handling of oral antineoplastic medications: Focus on targeted therapeutics in the home setting. Journal of Oncology Pharmacy Practice 23:5, pages 350-378.
Crossref
Crossref
Mika Sato-Nakai, Kosuke Kawashima, Toshito Nakagawa, Yukako Tachibana, Miyuki Yoshida, Kenji Takanashi, Peter N. Morcos, Martin Binder, David J Moore & Li Yu. (2017) Metabolites of alectinib in human: their identification and pharmacological activity. Heliyon 3:7, pages e00354.
Crossref
Crossref
Mercedes Barzi, Francis P. Pankowicz, Barry Zorman, Xing Liu, Xavier Legras, Diane Yang, Malgorzata Borowiak, Beatrice Bissig-Choisat, Pavel Sumazin, Feng Li & Karl-Dimiter Bissig. (2017) A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism. Nature Communications 8:1.
Crossref
Crossref
Heng Lin, Shuimei Luo, Lina Li, Sijing Zhou, Ruifen Shen, Haitao Yang, Yupeng Wu & Xianhe Xie. (2017) Efficacy and safety of antitumor agents plus radiotherapy compared with radiotherapy alone for brain metastases from lung cancer. Molecular and Clinical Oncology 6:3, pages 296-306.
Crossref
Crossref
F. Couñago, A. Rodríguez, P. Calvo, J. Luna, J. L. Monroy, B. Taboada, V. Díaz & N. Rodríguez de Dios. (2016) Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). Clinical and Translational Oncology 19:1, pages 31-43.
Crossref
Crossref
Peter Ballard, James W.T. Yates, Zhenfan Yang, Dong-Wan Kim, James Chih-Hsin Yang, Mireille Cantarini, Kathryn Pickup, Angela Jordan, Mike Hickey, Matthew Grist, Matthew Box, Peter Johnström, Katarina Varnäs, Jonas Malmquist, Kenneth S. Thress, Pasi A. Jänne & Darren Cross. (2016) Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clinical Cancer Research 22:20, pages 5130-5140.
Crossref
Crossref
Hiroyuki Kobayashi, Kazuhiro Sato, Takenori Niioka, Masahide Takeda, Yuji Okuda, Mariko Asano, Hiroshi Ito & Masatomo Miura. (2016) Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib. Medical Oncology 33:6.
Crossref
Crossref
Jaeki Min, Kexiao Guo, Praveen K. Suryadevara, Fangyi Zhu, Gloria Holbrook, Yizhe Chen, Clementine Feau, Brandon M. Young, Andrew Lemoff, Michele C. Connelly, Michael B. Kastan & R. Kiplin Guy. (2016) Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents. Journal of Medicinal Chemistry 59:2, pages 559-577.
Crossref
Crossref
Youwei Bi, Jiexin Deng, Daryl J. Murry & Guohua An. (2015) A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans. The AAPS Journal 18:1, pages 228-238.
Crossref
Crossref
Ching-Heng Lin, Kuo-Hsuan Hsu, Shih-Ni Chang, Hsi-Kai Tsou, Jason Sheehan, Meei-Ling Sheu & Hung-Chuan Pan. (2015) Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan. Radiation Oncology 10:1.
Crossref
Crossref
Xing Liu, Yuanfu Lu, Xinfu Guan, Bingning Dong, Hemantkumar Chavan, Jin Wang, Yiqing Zhang, Partha Krishnamurthy & Feng Li. (2015) Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism. Biochemical Pharmacology 97:1, pages 111-121.
Crossref
Crossref
Steven Lacy, Bih Hsu, Dale Miles, Dana Aftab, Ronghua Wang & Linh Nguyen. (2015) Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites. Drug Metabolism and Disposition 43:8, pages 1190-1207.
Crossref
Crossref
Michael D. Prados, Sara A. Byron, Nhan L. Tran, Joanna J. Phillips, Annette M. Molinaro, Keith L. Ligon, Patrick Y. Wen, John G. Kuhn, Ingo K. Mellinghoff, John F. de Groot, Howard Colman, Timothy F. Cloughesy, Susan M. Chang, Timothy C. Ryken, Waibhav D. Tembe, Jeffrey A. Kiefer, Michael E. Berens, David W. Craig, John D. Carpten & Jeffrey M. Trent. (2015) Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-Oncology 17:8, pages 1051-1063.
Crossref
Crossref
Hiroyuki Kobayashi, Kazuhiro Sato, Takenori Niioka, Hajime Miura, Hiroshi Ito & Masatomo Miura. (2015) Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non–Small-Cell Lung Cancer. Clinical Lung Cancer 16:4, pages 274-281.
Crossref
Crossref
Shuimei Luo, Long Chen, Xiuping Chen & Xianhe Xie. (2015) Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases. Oncotarget 6:18, pages 16725-16734.
Crossref
Crossref
Feng Wang, Fangling Ning, Changmin Liu, Yanzhang Hao, LiMian Li, Zeshun Yu, Shaoshui Chen & Baosheng Li. (2014) Comparison of Gefitinib Versus VMP in the Combination with Radiotherapy for Multiple Brain Metastases from Non-small Cell Lung Cancer. Cell Biochemistry and Biophysics 71:2, pages 1261-1265.
Crossref
Crossref
Satoshi Igawa, Masashi Kasajima, Mikiko Ishihara, Michiko Kimura, Yasuhiro Hiyoshi, Hideyuki Niwa, Seiichiro Kusuhara, Shinya Harada, Maiko Asakuma, Sakiko Otani, Ken Katono, Jiichiro Sasaki & Noriyuki Masuda. (2014) Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation. Cancer Chemotherapy and Pharmacology 74:5, pages 939-946.
Crossref
Crossref
Darren A.E. Cross, Susan E. Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A. Nebhan, Paula J. Spitzler, Jonathon P. Orme, M. Raymond V. Finlay, Richard A. Ward, Martine J. Mellor, Gareth Hughes, Amar Rahi, Vivien N. Jacobs, Monica Red Brewer, Eiki Ichihara, Jing Sun, Hailing Jin, Peter Ballard, Katherine Al-Kadhimi, Rachel Rowlinson, Teresa Klinowska, Graham H.P. Richmond, Mireille Cantarini, Dong-Wan Kim, Malcolm R. Ranson & William Pao. (2014) AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. Cancer Discovery 4:9, pages 1046-1061.
Crossref
Crossref
Solange Peters, Stefan Zimmermann & Alex A. Adjei. (2014) Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions. Cancer Treatment Reviews 40:8, pages 917-926.
Crossref
Crossref
Hye-Ryoun Kim, Jae Chol Lee, Young-Chul Kim, Kyu-Sik Kim, In-Jae Oh, Sung Yong Lee, Tae Won Jang, Min Ki Lee, Kyeong-Cheol Shin, Gwan Ho Lee, Jeong-Seon Ryu, Seung Hoon Jang, Ji Woong Son, Jeong Eun Lee, Sun Young Kim, Hee Joung Kim & Kye Young Lee. (2014) Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment. Lung Cancer 83:2, pages 252-258.
Crossref
Crossref
Shu-Yan Han, Hai-Yu Zhao, Ning Zhou, Fei Zhou & Ping-Ping Li. (2014) Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes. Journal of Ethnopharmacology 151:1, pages 210-217.
Crossref
Crossref
Michael Tagen & Clinton F. Stewart. 2014. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
625
659
.
Yan Chen, Mengzhao Wang, Wei Zhong & Jing Zhao. (2013) Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. Lung Cancer 82:2, pages 313-318.
Crossref
Crossref
Jian Meng. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
5
.
Jyoti Sharma, Hua Lv & James M. Gallo. (2013) Intratumoral Modeling of Gefitinib Pharmacokinetics and Pharmacodynamics in an Orthotopic Mouse Model of Glioblastoma. Cancer Research 73:16, pages 5242-5252.
Crossref
Crossref
Hua Lv, Fan Wang, M. V. Ramana Reddy, Qingyu Zhou, Xiaoping Zhang, E. Premkumar Reddy & James M. Gallo. (2012) Screening candidate anticancer drugs for brain tumor chemotherapy: Pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues. Investigational New Drugs 30:6, pages 2263-2273.
Crossref
Crossref
Mike Dennis, Michelle Davies, Stuart Oliver, Roy D’Souza, Laura Pike & Paul Stockman. (2012) Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia. Cancer Chemotherapy and Pharmacology 70:3, pages 461-469.
Crossref
Crossref
Gayathri T. Selvarajah, Monique. H. Verheije, Marja Kik, Adri Slob, Peter J.M. Rottier, Jan A. Mol & Jolle Kirpensteijn. (2012) Expression of epidermal growth factor receptor in canine osteosarcoma: Association with clinicopathological parameters and prognosis. The Veterinary Journal 193:2, pages 412-419.
Crossref
Crossref
Brian J. Trummer, Vandana Iyer, Sathy V. Balu-Iyer, Robert O'Connor & Robert M. Straubinger. (2012) Physicochemical Properties of Epidermal Growth Factor Receptor Inhibitors and Development of a Nanoliposomal Formulation of Gefitinib. Journal of Pharmaceutical Sciences 101:8, pages 2763-2776.
Crossref
Crossref
Peter Stopfer, Kristell Marzin, Hans Narjes, Dietmar Gansser, Mehdi Shahidi, Martina Uttereuther-Fischer & Thomas Ebner. (2011) Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemotherapy and Pharmacology 69:4, pages 1051-1061.
Crossref
Crossref
Takuya ArakiHideaki YashimaKimihiro ShimizuTohru AomoriTadahiro HashitaKyoichi KairaTomonori NakamuraKoujirou Yamamoto. (2012) Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib. Clinical Medicine Insights: Oncology 6, pages CMO.S7340.
Crossref
Crossref
Jiri Horak, Jeff White, Adrian L. Harris, Mark Verrill, James Carmichael, Alison Holt, Mireille Cantarini, Merran Macpherson, Alan Swaisland, Helen Swaisland & Chris Twelves. (2011) The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemotherapy and Pharmacology 68:6, pages 1485-1495.
Crossref
Crossref
Frauke Müller, Hendrik Riesenberg, Peter Hirnle, Hans-Björn Gehl, Paul Düwel & Martin Görner. (2011) Komplette Remission multifokaler zerebraler Metastasen bei chemotherapierefraktärem NSCLC durch Monotherapie mit GefitinibComplete remission of multiple brain metastases of non-small cell lung cancer induced by gefitinib monotherapy. Strahlentherapie und Onkologie 187:12, pages 826-830.
Crossref
Crossref
Dongyang Liu, Ji Jiang, Li Zhang, Fenlai Tan, Yingxiang Wang & Pei Hu. (2011) Metabolite characterization of a novel anti‐cancer agent, icotinib, in humans through liquid chromatography/quadrupole time‐of‐flight tandem mass spectrometry. Rapid Communications in Mass Spectrometry 25:15, pages 2131-2140.
Crossref
Crossref
Matthias Scheffler, Paola Di Gion, Oxana Doroshyenko, Jürgen Wolf & Uwe Fuhr. (2011) Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics 50:6, pages 371-403.
Crossref
Crossref
Julie Scholler & Dominique Levêque. (2011) Molecular pharmacokinetic determinants of anticancer kinase inhibitors in humans. Oncology Reviews 5:2, pages 77-92.
Crossref
Crossref
Maricla Galetti, Roberta R. Alfieri, Andrea Cavazzoni, Silvia La Monica, Mara Bonelli, Claudia Fumarola, Paola Mozzoni, Giuseppe De Palma, Roberta Andreoli, Antonio Mutti, Marco Mor, Marcello Tiseo, Andrea Ardizzoni & Pier Giorgio Petronini. (2010) Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines. Biochemical Pharmacology 80:2, pages 179-187.
Crossref
Crossref
Young Joo Lee, Hye Jin Choi, Se Kyu Kim, Joon Chang, Jin Wook Moon, In Kyu Park, Joo‐Hang Kim & Byoung Chul Cho. (2010) Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall‐cell lung cancer. Cancer 116:5, pages 1336-1343.
Crossref
Crossref
Shu-Feng Zhou. 2010. Supportive Cancer Care with Chinese Medicine. Supportive Cancer Care with Chinese Medicine
293
340
.
Nielka P. van Erp, Hans Gelderblom & Henk-Jan Guchelaar. (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treatment Reviews 35:8, pages 692-706.
Crossref
Crossref
Yuri Rukazenkov, Georgina Speake, Gayle Marshall, Judith Anderton, Barry R. Davies, Robert W. Wilkinson, D. Mark Hickinson & Alan Swaisland. (2009) Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?. Anti-Cancer Drugs 20:10, pages 856-866.
Crossref
Crossref
Xiaohai Li, Theodore M. Kamenecka & Michael D. Cameron. (2009) Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Gefitinib: Implications for Pulmonary and Hepatic Toxicities. Chemical Research in Toxicology 22:10, pages 1736-1742.
Crossref
Crossref
Claudio Festuccia, Giovanni Luca Gravina, Leda Biordi, Sandra D'Ascenzo, Vincenza Dolo, Corrado Ficorella, Enrico Ricevuto & Vincenzo Tombolini. (2009) Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. The Prostate 69:14, pages 1529-1537.
Crossref
Crossref
Stephanie Chhun, Celine Verstuyft, Nathalie Rizzo‐Padoin, Guy Simoneau, Laurent Becquemont, Ilana Peretti, Alan Swaisland, Robert Wortelboer, Jean Francois Bergmann & Stephane Mouly. (2009)
Gefitinib–phenytoin interaction is not correlated with the
14
C‐erythromycin breath test in healthy male volunteers
. British Journal of Clinical Pharmacology 68:2, pages 226-237.
Crossref
Crossref
Shenglin Ma, Yaping Xu, Qinghua Deng & Xinmin Yu. (2009) Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer 65:2, pages 198-203.
Crossref
Crossref
Hyeon Gyu Yi, Hye Jin Kim, Yu Jung Kim, Sae-Won Han, Do-Youn Oh, Se-Hoon Lee, Dong-Wan Kim, Seock-Ah Im, Tae-You Kim, Chul Soo Kim, Dae Seog Heo & Yung-Jue Bang. (2009) Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 65:1, pages 80-84.
Crossref
Crossref
Marie P. Piechocki, Susan K. Dibbley, Fulvio Lonardo & George H. Yoo. (2007) Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu. International Journal of Cancer 122:8, pages 1722-1729.
Crossref
Crossref
Naoki Ishiguro, Masanobu Oyabu, Toshihiro Sato, Tomoji Maeda, Hironobu Minami & Ikumi Tamai. (2007) Decreased Biosynthesis of Lung Surfactant Constituent Phosphatidylcholine Due to Inhibition of Choline Transporter by Gefitinib in Lung Alveolar Cells. Pharmaceutical Research 25:2, pages 417-427.
Crossref
Crossref
Tatsuro Fukuhara, Yasuo Saijo, Tomohiro Sakakibara, Akira Inoue, Naoto Morikawa, Masayuki Kanamori, Ichiro Nakashima & Toshihiro Nukiwa. (2008) Successful Treatment of Carcinomatous Meningitis with Gefitinib in a Patient with Lung Adenocarcinoma Harboring a Mutated EGF Receptor Gene. The Tohoku Journal of Experimental Medicine 214:4, pages 359-363.
Crossref
Crossref
Niklaus Dürmüller, Philippe Guillaume, Pierre Lacroix, Roger D. Porsolt & Paul Moser. (2007) The use of the dog electroencephalogram (EEG) in safety pharmacology to evaluate proconvulsant risk. Journal of Pharmacological and Toxicological Methods 56:2, pages 234-238.
Crossref
Crossref
Chi Wu, Yun Long Li, Zhao Meng Wang, Zhang Li, Tong Xiao Zhang & Zhong Wei. (2007) Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 57:3, pages 359-364.
Crossref
Crossref
Ebba Bergman, Patrik Forsell, Eva M. Persson, Lars Knutson, Paul Dickinson, Robert Smith, Helen Swaisland, Matthew R. Farmer, Mireille V. Cantarini & Hans Lennernäs. (2007) Pharmacokinetics of gefitinib in humans: The influence of gastrointestinal factors. International Journal of Pharmaceutics 341:1-2, pages 134-142.
Crossref
Crossref
Jing Li, Ming Zhao, Ping He, Manuel Hidalgo & Sharyn D. Baker. (2007) Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes. Clinical Cancer Research 13:12, pages 3731-3737.
Crossref
Crossref
Vladimir Beljanski. 2007. xPharm: The Comprehensive Pharmacology Reference. xPharm: The Comprehensive Pharmacology Reference
1
5
.
Mary J. Cismowski. 2007. xPharm: The Comprehensive Pharmacology Reference. xPharm: The Comprehensive Pharmacology Reference
1
4
.
Jing Li, Mats O. Karlsson, Julie Brahmer, Avery Spitz, Ming Zhao, Manuel Hidalgo & Sharyn D. Baker. (2006) CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors. JNCI: Journal of the National Cancer Institute 98:23, pages 1714-1723.
Crossref
Crossref
Erik Samén, Jan-Olov Thorell, Anna Fredriksson & Sharon Stone-Elander. (2006) The tyrosine kinase inhibitor PD153035: implication of labeling position on radiometabolites formed in vitro. Nuclear Medicine and Biology 33:8, pages 1005-1011.
Crossref
Crossref
Ji-Quan Wang, Mingzhang Gao, Kathy D. Miller, George W. Sledge & Qi-Huang Zheng. (2006) Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters 16:15, pages 4102-4106.
Crossref
Crossref
Jie Ling, Kim A. Johnson, Zhuang Miao, Ashok Rakhit, Michael P. Pantze, Marta Hamilton, Bert L. Lum & Chandra Prakash. (2006) METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS. Drug Metabolism and Disposition 34:3, pages 420-426.
Crossref
Crossref
David McKillop, Elizabeth A. Partridge, John V. Kemp, Mike P. Spence, Jane Kendrew, Sharon Barnett, Phillippa G. Wood, Petrina B. Giles, Andrew B. Patterson, Francis Bichat, Nicolas Guilbaud & Trevor C. Stephens. (2005) Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Molecular Cancer Therapeutics 4:4, pages 641-649.
Crossref
Crossref
Helen C Swaisland, Robert P Smith, Alison Laight, David J Kerr, Malcolm Ranson, Clive H Wilder-Smith & Thierry Duvauchelle. (2005) Single-Dose Clinical Pharmacokinetic Studies of Gefitinib. Clinical Pharmacokinetics 44:11, pages 1165-1177.
Crossref
Crossref